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Abstract Objective:To systematically evaluate the quality of the development of guidelines for the management of
chronic obstructive pulmonary disease (COPD). Methodology: MEDLINE and Excerpta Medica search for published
guidelines, followed by independent evaluation by two reviewers, according to previously reported guideline develop-
mentqualitycriteria, on a three-point scale.Results:Five national COPD guidelines and two international COPDguide-
lines were retrieved.Reviewers demonstrated good inter-observer agreement in assessing the10 combined guideline
development criteria for the seven guidelines [k= 0.66].Guidelines were only partlymulti-disciplinary, with little or no
consumer input, were up to 48 pages in length, and often lacked practical summaries ormanagement flowchartswhich
couldhave facilitatedretrievalof keymanagementrecommendations.Almost allthepaperswerebaseduponaconsensus
approach, rather than evidence based, andmethods of resolution of differences of opinionwere not stated.Patient out-
comes, ethical and medico-legal implications were not addressed and six of the guidelines were sponsored directly or
indirectly by a single drug company.Conclusions: In spite of COPD guidelines beingreported bymajornationalbodies for
over a decadenow, most fail tomeet importantcriteria forhigh-qualityguideline development, and evaluation of clinical
impact remainsundetermined.r2002 Elsevier Science Ltd.Allrights reserved
Available online athttp://www.sciencedirect.com
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Economic pressures from rising health-care costs, con-
sumer expectations and corporatisation in health-care
provision have increasingly directed the focus of health-
care away from thepatient to the health-care system (1),
and consequently to thewayhealth-care services arede-
livered. The promotion of clinical practice guidelines,
based on the best available evidence, has resulted partly
from the demonstration of considerable variations in
clinical practice (2^7) which could not be explained by
underlyingdi¡erences inpopulationrisk factors or sever-
ity of disease.Variation in patient treatment, and hence
costs, without improved health outcomes raises ques-
tions about the optimal use of limited resources. Evi-
dence-based guidelines which link processes to
outcomes provide a mechanism for improving e⁄ciencyCorrespondence should be addressed to: Associate Prof. Brian Smith,
Director,Clinical Epidemiology andHealthOutcomesUnit,TheQueen
Elizabeth Hospital, 28Woodville Road,Woodville South, SA. 5011,
Australia.Fax: 08 8222 6042; E-mail: brian.smith@nwahs.sa.gov.auand outcomes. However, despite the proliferation of
guidelines, there is limited evidence of their uptake in
clinical settings, and even less evidence of their impact
on patient health outcomes (8). Reviews of guidelines of
clinical topics other than chronic obstructive pulmonary
disease (COPD) have demonstrated poor adherence to
guidelinemethodological standards (7,9).
One barrier to guideline uptake is physician concern
about the intent and validity of these documents (10).
Further speci¢c attributes reported in the literature
that determine whether clinical practice guidelines are
used in practice include the clarity and speci¢city of the
guidelines (11), the strength of the evidence and its
susceptibility to bias (12).Without e¡ective methods to
translate evidence into changes in clinical practice, po-
tential bene¢ts for patients will not be realised (13).
COPD management guidelines have been reported in
the international biomedical literature since at least1987,
and have diverse contents (14).However, there is no evi-
dence that these guidelines have been widely adopted in
the health-care system, particularly in primary care, or
38 RESPIRATORYMEDICINEimpacted upon patient outcomes. Nor has there been
evaluation of either the quality of guideline development
or the strength of the evidenceuponwhichCOPDguide-
lines are based.
COPD is the ¢fth leading cause of mortality and bur-
den of disease for the world, accounting for 4.2% of
deaths worldwide (15).Given this burden of disease, and
the associated health-care resources utilised, our aim
was to systematically review the quality of the develop-
ment of published guidelines for the inpatient manage-
ment of COPD.
METHODS
Guidelines for themanagementofCOPDwere identi¢ed
by a search of MEDLINE and Excerpta Medica from their
commencement to 2001, using terms forCOPD (lungdis-
easesFobstructive, obstructive airways disease, em-
physema, chronic air£ow limitation, chronic obstructive
lung disease) and guidelines (algorithms, critical path-
ways, guidelines, standards, optimal assessment, prac-
tice guidelines).
Selection criteria
K The guidelinewaswrittenwith clearly statedprimary
objectives relevant to COPDmanagement.
K The latest guideline version available from an
institution or society was used.
K Guidelines prepared for an exclusive and narrow
audience were excluded, for example, for general
practice or nursing only.
The quality of guidelines developed for the manage-
ment of patients with COPD was assessed using the
eight criteria of Ward (16); applicability, validity (including
assessment of strength of evidence), reproducibility, clinical
£exibility, clarity, multi-disciplinary, documentation, and
scheduled review.These eight criteria are consistent with
those used by Grilli et al. (9), Shaneyfelt et al. (7) and
other guideline appraisal instruments (17). In view of in-
creasing interest in the implications of guideline use, we
added two further criteria, the demonstration of consid-
eration of medico-legal implications (18^20), and of ethi-
cal considerations (21,22). Table 1 outlines the
composition of each of the ¢nal10 criteria.
A thoracic physician (PF) and an epidemiologist/scien-
tist (AC) with expertise in clinical content and systema-
tic reviews, independently evaluated the guidelines that
met the selection criteria, using a scoring system of the
extent to which each of the quality criteria were ad-
dressed; three for fully addressed, two for partially, and
one for not at all.Extreme disagreements (score of three
vs. one) between the raters were identi¢ed by a third
party (KH), and further reviewoccurred. A kappa statis-
tic (23) was performed on the ¢nal ratings to assess
inter-observer agreement.RESULTS
Seven COPD guidelines met the selection criteria. Six
guidelines originated from thoracic or respiratory socie-
ties (seeTable 2) and the most recent, the Global initia-
tive for chronic obstructive lung disease (GOLD), was
initiated by a collaboration between the World Health
Organisation (WHO) and the National Heart, Lung and
Blood Institute (NHLBI). All included management re-
commendations for inpatients. Six included outpatient
care recommendations (CTS (24), ERS (25), ATS (26),
SAPS (27), TSANZ (28), GOLD (29)), four included
emergency and general practice recommendations (BTS
(30), ERS (25), SAPS (27),GOLD (29)), whilst two (ATS
(26),TSANZ (28)) focussedparticularly on hospital man-
agement (both inpatients and outpatients).The ATS (26),
SAPS (27) and GOLD (29) guidelines also discussed sur-
gicalmanagement issues.
Quality of guideline development
The ¢ndings of the independent reviewers, in relation to
the10 criteria speci¢ed inTable1, are summarised below,
with a graphical summaryof the associatedratings in Fig.
1, and actual scored ratings of the two independent re-
viewers provided in Appendix1.
Applicability
All of the guidelines listed inTable 2 described thepatient
population and includedde¢nitions of the diseaseCOPD.
Arange of COPD sub-categories (BTS) andpathophysio-
logical processes (CTS) were described. The published
guidelines targeted an audience of principally general
practitioners (SAPS, CTS) or physicians (ERS, TSANZ),
or didnot specify a target audience (ATS), or were aimed
at a very broad audience (GOLD).Caregivers were also
mentioned as being part of the target audience for one
guideline (SAPS). There was a range of guideline objec-
tives, including early detection, non-drug interventions
and smoking intervention (TSANZ, GOLD), acute and
ongoing care (BTS), and also epidemiology, risk factors,
prognosis and staging (ATS,GOLD).Guidelines included
managementrecommendationsrelevant to inpatient and
outpatient care, with emphasis in the BTS and ERS
guidelines upon emergency department and primary
care, respectively.GOLD had the broadest range of ob-
jectives, including an internationalpublic health emphasis
and disease prevention.This critique relates to one of six
chapters, namely ‘‘Management of COPD’’ in which four
components were identi¢ed: ‘‘Assess and Monitor Dis-
ease,’’ ‘‘Reduce Risk Factors,’’ ‘‘Manage Stable COPD’’
and ‘‘Manage Exacerbations.’’
TABLE 1. Criteria for evaluation ofguideline developmentquality; 1^8: fromWard and Grieco (16), in additionto two furthercriteria: 9 (18^20), and10 (21,22).
Criteria Items
1. Applicability states health problem, describes patientpopulation, and de¢nes intervention, andrelates to providers andpatients
2.Validity describeshealth outcomes, intervention costings, consensusmethods, con£ict with other guidelines, methods to identify and synthesise evidence,
strength of evidence
3.Reproducibility references sources of informationused, and documents literature reviewprocesses byexperts/outside panel
4.Clinical £exibility describeshow to handle clinical exceptions
5.Clarity unambiguoususe of headings, use of £owcharts, and facilitation of easyretrieval ofmajor points andrecommendations
6.Multi-disciplinary lists disciplines thatdeveloped the guidelines
7.Documentation date of publication and an indication ofthe edition or version
8. Schedule review date of review speci¢ed
9.Medico-legal consideration ofmedico-legal implications
10.Ethical statementof potential con£icts of interest, including sponsorship
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TABLE 2. Guidelines formanagementof COPDretrieved according to selection criteria
Title Society/Association Date
Guidelines for the assessment andmanagementof COPD CanadianThoracic Society (CTS) Aug1992
Guidelines for themanagementof COPD Thoracic Societyof Australia and NewZealand (TSANZ) July1995
Optimal assessment andmanagementof COPD European Respiratory Society (ERS) August1995
Standards for the diagnosis and care of patientswith COPD AmericanThoracic Society (ATS) November1995
BTS guidelines for themanagementof COPD BritishThoracic Society (BTS) December1997
Guidelines for themanagementof COPD South African Pulmonology Society (SAPS) August1998
GOLD National Heart,Lungand Blood Institute (NHLBI)/World Health Organisation
(WHO) (international)
April 2001
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FIG. 1. The qualityof COPD guideline developmentratedby two reviewersusingcriteria fromTable1.
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Assessment of items within the validity criteria, found
that health outcomes were broadly discussed in the
ERS, ATS and CTS guidelines, and speci¢cally described
in relation to each treatment for the BTS, TSANZ and
GOLD guidelines. Costings of interventions were men-
tioned in several very speci¢c instances in the TSANZ
andATS guidelines.Therewas little cost content in other
guidelines. As GOLD was an international document,
therewas little scope for it to consider costs of interven-
tions.
ERS and BTS guidelines described a structured ap-
proach to guideline development, with a series of work-
ing group meetings. OneThoracic Society sponsored a
workshop (CTS), and a furtherThoracic Society utilised
a group of ¢ve Respiratory Physician authors (TSANZ),
who held a simple consensus meeting to summarise dis-
cussions, although this was not stated in the published
guidelines. The ATS, TSANZ, and CTS did not outline
the methods used to identify evidence, synthesise evi-
dence, or reach consensus. There was no indication of
evaluation of the strength of evidence behind recom-
mendations made, such as according to the categories
proposed by Eccles et al. (31,32) for any of the guidelines,
except for GOLD.
GOLD guidelines were developed over several years
by consensus among international experts, namely‘‘a distinguished group of professionals from the ¢elds
of respiratory medicine, epidemiology, socioeconomics,
public health, and health education’’. In addition, there
was widespread consultation with expert individuals
and organisations from an extraordinary number of
countries. It has not been made clear, however, as to
the area of expertise of each individual consulted,
although themethodsused to develop theguidelinewere
explicit in the document. Finally, the guideline was taken
to the fullmembership of theAmericanThoracic Society
and European Respiratory Society, then to the NHLBI
andWHObefore ¢nal publication.Methods for reaching
consensuswere stated, gradingof levels of evidencewere
allocated by expert panel for critical statements and
management recommendations. Con£ict with other
guidelines were not discussed.
Reproducibility
Guideline citation of the published literature ranged
from no references (apart from recommended reading
of ¢ve papers) for the SAPS guideline, to 265 references
for the ATS guideline. Review of the literature for the
CTS guideline was by the Canadian Thoracic Society
Standards Committee, by a limited multi-disciplinary
working group for the SAPS, and included discussion
with ‘‘colleagues from North America’’ for the ERS
42 RESPIRATORYMEDICINEguideline. No statements were provided about search
and review strategies in other guidelines. In GOLD, the
sections relating to Management of COPD were accom-
panied by 314 references, provided by expert working
parties.
Clinical £exibility
Therewas little or no discussion in anyguidelines regard-
ing management of clinical exceptions to broad recom-
mendations, as would be expected in real-life situations,
apart from ERS and GOLD. GOLD refers to patient
variability in most sections, particularly in the Manage-
ment chapter.
Clarity
The overall length and structure of the guidelines limited
easy retrieval of the range of recommendations. Papers
other thanGOLDhad an average length of 21pages, ran-
ging from nine (CTS, SAPS) up to 43 pages (ATS). The
‘‘Managementof COPD’’chapter of GOLDwas 48pages.
Both the BTS and TSANZ guidelines provided summary
overviews.GOLD and the ATS provided £ow charts to
guide treatment in speci¢c circumstances.The BTS sum-
mary of guidelines, presented as a two-page document
with clear diagrams, could provide clinicians with a clear
working guide. ERS management algorithms were de-
tailed, but legible and logical.The CTS guidelinewas pre-
sented in a narrative format without summaries or
management algorithms, which is not ideal for rapid
scanning for recommendations. All GOLD statements
and recommendations had a level of evidence, and that
evidence was clearly referenced. It also included boxes
of key points as summaries, with levels of evidence
clearly presented.
Multi-disciplinary
All of the guidelines provided a list of participants who
developed the guidelines, but none speci¢cally included
purchasers, patients or consumers. BTS processes in-
cluded consultation with general practitioners, nurses
and lay groups. The SAPS guideline included input from
medical schools, physiotherapists, pharmacologists, and
anaesthetists, but no general practitioners, though it
was stated to be directed to general practice. The ATS
guideline had input from one registered nurse and a
radiotherapist. TSANZ and CTS guidelines input was
from respiratory physicians, and did not include consid-
eration of advantages of multi-disciplinary input (12).
GOLD guidelines were reviewed by a long list of partici-
pants and organisations, with expert panel input from
¢elds of respiratory medicine, epidemiology, socioeco-
nomics, public health and health education. Speci¢careas of clinical expertise (general practice, nursing, al-
lied health) were not explicit.
Documentation/schedule review
The ATS guidelinewas a complete revision of1987 guide-
lines for ATS. Other documents represented ¢rst time
publications, and schedules for review were not stated.
Medico-legal implications
No guidelines discussed the medico-legal implications of
non-adherence to practice recommendations.
Ethical implications
A single drug company provided direct sponsorship for
the SAPS, BTS, ERS, ATS, and CTS guidelines, and the
TSANZ guidelines were indirectly supported from the
same source. For development of the GOLD guidelines,
sources of educational grants were identi¢ed, including
16 pharmaceutical and chemical companies. Six of the
guideline groups acknowledged the ¢nancial support re-
ceived but none included statements about potential
con£icts of interest. Apart from GOLD, guidelines in-
cluded speci¢c unreferenced recommendations compar-
ing use of medications between conditions, such as
‘‘anticholinergic agents aremore e¡ective in COPD than
in asthma’’ (25). There are also unreferenced compari-
sons between medications, such as ‘‘once symptoms be-
come continuous, ipatropium bromide should be given,
as it provides bene¢ts over b2 agonists by producing few-
er side e¡ects, moreprolonged action and less tachyphy-
laxis’’ (33).
Inter-reviewer agreement
The two independent reviewers were in complete dis-
agreement (one vs. three) for only seven out of a total of
133 items, and were asked to score those items again,
blinded to the assessment of the other reviewer. Follow-
ing this, the ¢nal inter-observer agreement, in relation
to the 10 guideline development criteria for each of the
six guidelines, was good. [k=0.66] (23). [Final reviewer
scoresFsee Appendix1.]
DISCUSSION
There has been increasing interest in clinical practice
guidelines and evidence-based medicine in recent years.
We therefore evaluated the quality of development of
guidelines for the major condition of COPD.We found
thatmuch of the development of publishedCOPDguide-
lines has not followed methodological standards, a ¢nd-
ing consistent with reports of guidelines relevant to
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and between the seven published COPD guidelines with
respect to development quality criteria; and there had
been little progress in development quality from1987 to
1998.The GOLD guideline (2001) was themost compre-
hensively developed to date, with recommendations
clearly linked to the evidence, including ratings of the
strength of the evidence. Six guidelines were sponsored
directly or indirectly by a single drug company, and the
seventh (GOLD) was sponsored by multiple companies,
although therewas almost no discussion of ethical impli-
cations or statements of potential con£ict of interest.
From this review, there are important unmet needs
displayed in the published COPD guidelines. Validity of
the processes of development of the published guidelines
was limited. There has been an emphasis upon medical
model consensus agreementrather than amulti-disciplin-
ary approach in some guidelines (12,34). A structured ap-
proach for retrieval, appraisal, rating and presentation of
the available evidence is important (34^37), yet lacking.
Little has been done to ensure the practical retrieval of
key recommendations in real-life clinical settings. These
limitations and a lack of clinician con¢dence in consensus-
and opinion-based statements (38)may impedeuptake of
guidelines by clinicians. Indeed, there has also been no
evaluation of the impact of published COPD guidelines
upon such clinical uptake, or upon patient outcomes.
Consumer participation was not reported for any of
the reviewed guidelines, apart from input of a lay group
for the BTS guideline. It is important that guidelines in-
clude consumers in development and implementation
(39,40) so that guideline priorities and embedded values
correspond to those of the targeted patient group
(41,42).
The inculpatory use of guidelines by plainti¡ lawyers
may be a concern for clinicians. Under United Kingdom
common law, the standard of minimal acceptable care is
based on responsible practice and discretion and not on
guidelines (20) while in the U.S., guidelines have already
featured in 6.6% of recent medico-legal cases (19,43). As
this issue is likely to become increasingly important, con-
sideration of medico-legal and ethical considerations
were included as criteria of development quality in our
review. Little consideration has been given to this area
in published COPD guidelines.
Our review has several limitations.The interpretation
of criteria such as clarity may be somewhat subjective.
However, unlike the review by Shaneyfelt et al. (7) we
chose not to use a composite score to rate guideline
quality, but instead chose to evaluate each criterion sepa-
rately and independently.We also used a three-point rat-
ing scale (as opposed to Shaneyfelt’sYes/No scale) to rate
eachguideline as this enables amore detailed assessment
of guideline quality, and we have demonstrated a good
level of agreement in ratings between two independent
observers.A further limitation of our review is that the reported
process of guideline developmentmay not fully re£ect all
thatwas performed.Wemadeno attempt to contact the
lead authors of any of the guidelines for clari¢cation of
the development process. Documentation of guideline
development is critical to allow readers to discern guide-
line development quality, and should be addressed in a
transparentmanner.
In our review, we did not include reports related spe-
ci¢cally to evaluation of interventions based upon im-
proving discharge from hospital, such as by use of a
comprehensive patient work up, and discharge criteria
checklists (44^46). These speci¢cally focussed reports
have demonstrated positive clinical outcomes, as well as
examples of methodologies for the evaluation of guide-
line impact.
The developmentofmulti-disciplinary, evidence-based
guidelines,with attention to theneeds of clinician andpa-
tient stakeholders, requires substantial e¡ort.The Brit-
ish Thoracic Society is moving to base its next COPD
guidelines on the highly structured evidence evaluations
providedbyCochrane reviews, as is theThoracic Society
of Australia and New Zealand. For further progress to
occur, there is a need for collaborative sharing of the
work e¡ort, and ongoing improvement through evalua-
tion and feedback.TheGOLDInitiativeundertook an ex-
tensive review of evidence and wide multi-disciplinary
international consultation over several years prior to re-
lease of the GOLD guidelines and its database (supple-
mented by the Cochrane database), has formed the
basis of the newTSANZ guidelines. As COPD is a condi-
tion ofmajormorbidity andmortality, it appears reason-
able that independent (or health service funded) sources
of support be obtained, particularly given the cost and
ethical implications ofmany guideline recommendations.
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ASSESSMENTOFGUIDELINESFORCOPD 45Appendix 1 The qualityof COPD guideline development, byTable1criteria: scored as 3: fully addressed, 2: partiallyor1: not
at all, by two independent reviewers [AC,PF].
Criteria ATS TSANZ CTS SAPS BTS ERS GOLD
Applicability
States health problem 3, 3 3, 3 2, 3 2, 3 3, 3 3, 3 3, 3
Describespatientpopulation 2, 3 2, 3 2, 3 2, 3 3, 3 3, 3 3, 3
De¢nes intervention 3, 3 3, 2 2, 2 3, 2 3, 3 3, 3 3, 3
Validity
Health outcomeslisted 3, 3 2, 3 2, 2 2, 2 3, 3 3, 3 3, 3
Costings of intervention 2, 2 1, 2 1,1 1,1 1,1 1,1 2, 2
Method for reachingconsensus 1,1 1,1 2, 2 3, 3 3, 3 2, 3 2, 3
Con£ictwith other guidelines 1,1 1,1 1,1 1,1 1, 2 2, 2 2,1
Methodused to identifyevidence 1,1 1,1 2,1 2, 2 3, 2 2,1 2, 2
Methodused to synthesise evidence 1,1 1,1 2,1 2, 3 2, 2 3, 3 2, 2
Reproducibility
References information sources 3, 3 2, 3 3, 2 2,1 3, 3 3, 3 3, 3
Documentreviewedbyexperts/outside panel 2,1 1,1 3, 3 3, 3 2,1 3, 2 3, 3
Clinical £exibility
Information aboutexceptions 2,1 2,1 1, 2 1,1 2, 2 2, 3 2, 3
Clarity
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